Smad4/DPC4
The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index.
Abstract
Smad4 or DPC4 belongs to a family of signal transduction proteins that are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor beta (TGF-β) signaling via several pathways. The gene acts as a tumour suppressor gene and inactivation of smad4/DPC4 is best recognised in pancreatic cancer. However, smad4/DPC4 is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers. Immunohistochemistry for smad4/DPC4 protein is most useful in separating benign/reactive conditions from pancreatic cancer in needle/core biopsies. In normal and reactive states, the protein is localised to the cytoplasm and nucleus, while the protein is lost in high-grade pancreatic intraepithelial neoplasia/carcinoma in situ and pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study involving 249 PDAC patients revealed that 43% lacked SMAD4 expression and 45% were positive.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“In pancreatic cancer, its inactivation is common, with immunohistochemistry effectively distinguishing benign from malignant states.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“Smad4/DPC4, activated by TGF-β signaling, acts as a tumor suppressor gene.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“Patients with intact SMAD4 expression exhibited significantly improved prognosis, with a median survival of 19.2 months compared to 14.7 months for those lacking SMAD4 [66,82].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“Genetic analysis showed concordance between SMAD4 expression and genetic status in 97% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
DPC4 gene in various tumor types.
Schutte, M. E. M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., et al. (1996) · PubMed · Cited by 672
Wilentz, R. E., Iacobuzio–Donahue, C. A., Argani, P., McCarthy, D. M., Parsons, J. L., Yeo, C. J., Kern, S. E., & Hruban, R. H. (2000) · PubMed · Cited by 591
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., Wu, C.-J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., et al. (2011) · Nature · doi:10.1038/nature09677 · Cited by 515
Dual role of the Smad4/DPC4 tumor suppressor in TGFβ-inducible transcriptional complexes
Liu, F., Pouponnot, C., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.23.3157 · Cited by 445
Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis
Miyaki, M., Iijima, T., Konishi, M., Sakai, K., Ishii, A., Yasuno, M., Hishima, T., Koike, M., Shitara, N., Iwama, T., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202642 · Cited by 436
The genomic landscape of small intestine neuroendocrine tumors
Banck, M. S., Kanwar, R., Kulkarni, A. A., Boora, G. K., Metge, F., Kipp, B. R., Zhang, L., Thorland, E. C., Minn, K. T., Tentu, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67963 · Cited by 324
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Roth, A. D., Delorenzi, M., Tejpar, S., Yan, P., Klingbiel, D., Fiocca, R., d'Ario, G., Cisar, L., Labianca, R., Cunningham, D., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs427 · Cited by 284
Research works printed but not linked: 1
- 10.1002/1097-0142(20010401)91:7<1332::aid-cncr1136>3.0.co;2-4 · doi:10.1002/1097-0142(20010401)91:7<1332::aid-cncr1136>3.0.co;2-4
Cited by
Zheng, L., Liang, H., Zhang, Q., Shen, Z., Sun, Y., Zhao, X., Gong, J., Hou, Z., Jiang, K., Wang, Q., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01495-y · Cited by 159
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Driver Gene Mutations and Epigenetics in Colorectal Cancer
Raskov, H., Søby, J. H., Troelsen, J. T., Bojesen, R. D., & Gögenür, I. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003393 · Cited by 107
Fang, T., Liang, T., Wang, Y., Wu, H., Liu, S., Xie, L., Liang, J., Wang, C., & Tan, Y. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01864-9 · Cited by 66
Molecular therapeutic strategies targeting pancreatic cancer induced cachexia
Yakovenko, A., Cameron, M. E., & Trevino, J. (2018) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v10.i9.95 · Cited by 64
Li, O., Li, L., Sheng, Y., Ke, K., Wu, J., Mou, Y., Liu, M., & Jin, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216391 · Cited by 46
Salvianti, F., Gelmini, S., Mancini, I., Pazzagli, M., Pillozzi, S., Giommoni, E., Brugia, M., Costanzo, F. D., Galardi, F., Luca, F. D., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01399-6 · Cited by 42
Giannis, D., Moris, D., & Barbas, A. S. (2021) · Cancers · doi:10.3390/cancers13051071 · Cited by 41
Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
Röcken, C., Amallraja, A., Halske, C., Opašić, L., Traulsen, A., Behrens, H., Krüger, S., Liu, A., Haag, J., Egberts, J., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00975-y · Cited by 37
Zhong, Z., Huang, Y., Hu, Q., He, W., Duan, B., Yan, X., Zhenjie, Y., Liang, W., Liu, Z., Peng, Z., et al. (2019) · Biomaterials Science · doi:10.1039/c9bm00404a · Cited by 24
Mašlanková, J., Večurkovská, I., Rabajdová, M., Kaťuchová, J., Kička, M., Gayova, M., & Katuch, V. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i33.4744 · Cited by 23
Ma, C., Liu, M., Feng, W., Rao, H., Zhang, W., Liu, C., Xu, Y., Wang, Z., Teng, Y., Yang, X., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1475 · Cited by 21
“7 It has been reported that the TGF-β pathway plays an oncogenic role in CRC. 7,8 As an important intracellular receptor signalling molecule in TGF-β signalling pathway, SMAD4 can enter the nucleus by forming homologous complexes alone or with other activated SMAD family members.”
BackgroundTGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance
Johansen, A. M., Forsythe, S. D., McGrath, C. T., Barker, G., Jimenez, H., Paluri, R. K., & Pasche, B. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0468 · Cited by 21
Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy
Sha, M., Gao, Y., Xu, Y., Li, X., Liu, C., & Li, S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03697-0 · Cited by 20
“This gene acts as a tumor suppressor gene and inactivation of smad4/DPC4 is most prominent in PC [150].”
SMAD4 variants and its genotype–phenotype correlations to juvenile polyposis syndrome
Cao, K., Plazzer, J., & Macrae, F. (2023) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-023-00267-z · Cited by 20
Hepatocyte-Specific Smad4 Deficiency Alleviates Liver Fibrosis via the p38/p65 Pathway
Wei, M., Yan, X., Xin, X., Chen, H., Hou, L., & Zhang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911696 · Cited by 19
Yu, S., Doyle, L. A., Hornick, J. L., & Mito, J. K. (2023) · Cancer Cytopathology · doi:10.1002/cncy.22777 · Cited by 17
“13,14 Loss of SMAD4 expression by immunohistochemistry (IHC) has been identified as a reliable marker for the diagnosis of PDAC in the appropriate context, including in small biopsy specimens.”
BackgroundWebb, B. M., Bryson, B. L., Williams-Medina, E., Bobbitt, J. R., Seachrist, D. D., Anstine, L. J., & Keri, R. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101162 · Cited by 17
Yang, W., Yan, X., Chen, R., Xin, X., Ge, S., Zhao, Y., Yan, X., & Zhang, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07376-8 · Cited by 16
“In mammals, eight different SMADs are further divided into three distinct classes: R-Smad (Smad1, 2, 3, 5, and 8), Co-Smad (Smad4), and I-Smad (Smad6 and 7) [21].”
Pepe, F., Pisapia, P., De, M. D. B., Conticelli, F., Malapelle, U., Troncone, G., & Martínez, J. C. (2020) · PubMed · doi:10.14670/hh-18-195 · Cited by 15
Wang, H., & Zheng, G. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01619-8 · Cited by 15
Yang, X., Zhang, Q., Li, S., Devarajan, R., Luo, B., Tan, Z., Wang, Z., Giannareas, N., Wenta, T., Ma, W., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02745-7 · Cited by 14
Li, K., Shu, D., Li, H., Lan, A., Zhang, W., Tan, Z., Huang, M., Tomasi, M. L., Jin, A., Yu, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06838-9 · Cited by 15
“SMAD4 functions as a common signal transducer in the transforming growth factor (TGF) superfamily [11].”
Loss of function SMAD4 nonstop mutations in human cancer
Bauer, A. H., Basta, D. W., Hornick, J. L., & Dong, F. (2023) · Histopathology · doi:10.1111/his.14880 · Cited by 13
Decoding pancreatic cancer: key risk factors across genetics and lifestyle
Sharma, R., Ghosh, R., Kumar, S., Komal, K., & Kumar, M. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2464563 · Cited by 13
“Approximately 55–60% of PDACs that develop through this sequential pathway exhibit mutational inactivation of SMAD4 [44].”
Genetic counseling and testing for hereditary hemorrhagic telangiectasia
Lam, S., Guthrie, K. S., Latif, M. A., & Weiss, C. R. (2021) · Clinical Genetics · doi:10.1111/cge.14050 · Cited by 12
Zhang, M., Kiyono, T., Aoki, K., Goshima, N., Kobayashi, S., Hiranuma, K., Shiraishi, K., Saya, H., & Nakahara, T. (2021) · Cancer Science · doi:10.1111/cas.15246 · Cited by 12
Yu, Y., Zou, Y., Hong, R., Chen, W., Chen, W., Chen, W., Wang, H., & Yu, Y. (2022) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12574 · Cited by 11
Liu, T., Zhang, X., Yan, X., Cheng, L., Yan, X., Zeng, F., Li, X., Chen, Z., Gu, J. H., & Zhang, J. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.98529 · Cited by 10
Identification of key regulators in Sarcoidosis through multidimensional systems biological approach
Tazyeen, S., Ahmed, M. M., Farooqui, A., Alam, A., Malik, M. Z., Saeed, M., Ahmad, I. S., Abohashrh, M., Singh, R. K. B., & Ishrat, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-05129-7 · Cited by 10
Non-coding RNAs Regulate the Pathogenesis of Aortic Dissection
Hu, Y., Cheng, X., Wu, N., Yang, T., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.890607 · Cited by 10
Global perspective on the genetic, epigenetic, and transcriptomic basis of gallbladder cancer
Das, D., Singh, P., Pal, M., Pandey, M., & Dixit, R. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104830 · Cited by 9
Song, K., Lee, H. S., Jia, L., Chelakkot, C., Rajasekaran, N., & Shin, Y. K. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.0067 · Cited by 8
“…of the SMAD4 gene, or complete loss of SMAD4 protein occur in multiple carcinomas causing uncontrolled tumorigenic proliferation either dependent or independent of TGF-β signaling (Bartsch et al., 1999; McCarthy and Chetty, 2018; Miyaki and Kuroki, 2003; Wan et al., 2021; Wilentz et al., 2000).”
Wu, K., Gong, W., Sun, H., Li, W., Chen, L., Duan, Y., Zhu, J., Zhang, H., & Ke, H. (2024) · Cancer Reports · doi:10.1002/cnr2.1976 · Cited by 8
“21 Previous study has reported that loss-of-function alterations in SMAD4 result in TGF-β being a tumor-promoting pathway through its interaction with other proteins.”
BackgroundIBSP Promotes Breast Cancer Bone Metastasis and Proliferation via BMP ‐ SMAD Signaling Pathway
Ding, W., Lv, D., Wang, M., & Pei, D.-S. (2024) · Cancer Reports · doi:10.1002/cnr2.2153 · Cited by 8
“SMAD4 is also called Co-SMAD [19], which is activated by TGF-β via serine– threonine receptor kinases phosphorylation [20].”
BackgroundZhao, S., Nan, L., Wang, Y., Wei, L., & Mo, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4858 · Cited by 8
Li, Y., Liu, P., & Wei, F. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12549 · Cited by 8
GPBAR1 Promotes Proliferation of Serous Ovarian Cancer by Inducing Smad4 Ubiquitination
Li, H., Zhao, J., & Shi, X. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000917 · Cited by 8
Chen, F., Zhong, C.-C., Song, C.-C., Chen, S.-W., He, Y., & Tan, X.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094505 · Cited by 7
Li, K., Li, Y., & Nakamura, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-49100-6 · Cited by 7
“SMAD4 (a.k.a DPC4), Suppressor of Mothers Against Decapentaplegic Homolog 4, also regulates gene expression by promoting the binding of multimeric complex to DNA 35 .”
Li, W., Wei, W., Hu, D., Tang, R., & Hu, Z. (2023) · Open Medicine · doi:10.1515/med-2022-0604 · Cited by 7
Maloney, S., Clarke, S. J., Sahni, S., Hudson, A. L., Colvin, E. K., Mittal, A., Samra, J. S., & Pavlakis, N. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05149-4 · Cited by 6
“The most common mutation being gene deletion (McCarthy and Chetty 2018).”
BackgroundWang, H., & Zheng, G. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.082 · Cited by 6
Yuan, X., Wu, Y., Yang, K., Liu, H., & Zhang, G. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5556653 · Cited by 6
“All TGF-β signaling molecules must be mediated by Smad4 protein to enter the nucleus, and Smad6 and 7 are inhibitors of this pathway [48, 49].”
BackgroundDespas, L., Vialet, L., Tusseau, M., Azemard, V., Beurier-Soulat, L., Tabosh, T. A., Auboiroux, C., Parrot, A., Blivet, S., Horn, X. L. G., et al. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2025-110797 · Cited by 5
Drivers of Pancreatic Cancer: Beyond the Big 4
Porcza, L. M., Ballesteros-Cillero, R., Lam, L. T., Maiello, C., & Leslie, N. R. (2025) · Cancers · doi:10.3390/cancers17142354 · Cited by 5
“The SMAD4 protein forms hetero-oligomers with other SMAD proteins in response to TGF β stimulation and, through effects on the transcription of its target genes, influences a diverse set of processes including cell cycle progression, cell migration, and angiogenesis [23].”
Sirolimus for the Treatment of Juvenile Polyposis in Childhood
Martín‐Masot, R., Autero, N. C., Pérez, P. O., Torcuato‐Rubio, E., Pedreño, L. V., Fernández, C. G., Blasco‐Alonso, J., & Navas‐López, V. M. (2021) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000646 · Cited by 5
Selven, H., Busund, L., Andersen, S., Pedersen, M. I., Lombardi, A. P. G., & Kilvaer, T. K. (2023) · Cancers · doi:10.3390/cancers15051448 · Cited by 5
Long Non-Coding RNAs and RNA-Binding Proteins in Pancreatic Cancer Development and Progression
Preckwinkel, P., Mir, K. U. I., Otto, F. W., Elrewany, H., Sinz, A., Hüttelmaier, S., Bley, N., & Gutschner, T. (2025) · Cancers · doi:10.3390/cancers17101601 · Cited by 4
Kuruma, A., Masuda, T., Sato, K., Kido, K., Motooka, D., Komura, N., Yokoi, T., Yoshihara, K., Kinose, Y., Hashimoto, K., et al. (2026) · Cancers · doi:10.3390/cancers18040651 · Cited by 4
“This domain is essential for homodimerization, heterodimerization, transcriptional activation, and nuclear localization of SMAD4 [35].”
Immunohistochemical detection of cancer genetic abnormalities
Le, M., Oishi, N., Mochizuki, K., & Kondo, T. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155109 · Cited by 4
Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection
Wang, H., He, M., Cong, W., & Dong, H. F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1653534 · Cited by 3
“This gene functions as a tumor suppressor, and the inactivation of Smad4/DPC4 is most prominently observed in pancreatic cancer (63).”
Dai, C., Zhao, Y., Zhang, H., Sultan, M. H., Huang, B., Tian, X., Jia, X., Li, H., Huang, F., & Wang, Y. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00976-8 · Cited by 3
“Our fi ndings not only elucidate the tumor suppressor role of SMAD4 in NSCLC but also provide a novel combined therapeutic strategy for NSCLC.”
Wismayer, R., Matthews, R., Whalley, C., Kiwanuka, J. P., Kakembo, F. E., Thorn, S., Wabinga, H., Odida, M., & Tomlinson, I. P. M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12967-3 · Cited by 3
“Juvenile polyposis syndrome, hereditary hemorrhagic telangiectasia, and pancreatic cancer result from deletions or mutations in the SMAD4 gene [36–38].”
BackgroundJhetam, Z., Martins-Furness, C., Slabber, C., Munro, O. Q., Nel, M., & Harmse, L. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112815 · Cited by 3
Abdalsada, H. K., Abdulsaheb, Y. S., Zolghadri, S., Al‐Hakeim, H. K., & Stanek, A. (2024) · Biomedicines · doi:10.3390/biomedicines12092015 · Cited by 3
SMAD4 mutations identified in Iranian patients with colorectal cancer and polyp.
Sadeghi, R. N., Saeedi, N., Sahba, N., & Sadeghi, A. (2021) · Gastroenterology and hepatology from bed to bench. · Cited by 3
A Rational Approach to the Diagnosis of Liver Metastases
Hu, S., & Allende, D. S. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100903 · Cited by 2
Peng, Y., Li, Y., Lo, H. H., Law, B. Y. K., & Wong, V. K. W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_6 · Cited by 2
Akça, D., Demiray, A. G., & Demirkan, N. Ç. (2025) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_739_24 · Cited by 2
Rauwerdink, P., Brosens, L. A. A., van Diepen, K. K., Ghedri, O. N., Kranenburg, O., Boerma, D., Witkamp, A. J., & van Grevenstein, H. M. U. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02613-2 · Cited by 2
The Computational Study of Toxic Heavy Metal Binding to Cancer‐Related Mutation Proteins
Chauhan, S., Kulharia, M., & Verma, S. K. (2025) · ChemistrySelect · doi:10.1002/slct.202505441 · Cited by 1
Preliminary study on pathogenic mechanism of first Chinese family with PNKD
Chen, F., Zhang, S., Liu, T., Liu, Y., Wang, Y., Zhang, G., & Liang, S. (2022) · Translational Neuroscience · doi:10.1515/tnsci-2022-0222 · Cited by 1
Dang, Y., Xu, Q., Liu, X., Wang, L., & Lin, C. (2022) · Medical Molecular Morphology · doi:10.1007/s00795-022-00333-w · Cited by 1
Li, X., Wang, Y., Wang, X., Shen, Y., Yuan, Y., He, Q., Mao, S., Wu, C., & Zhou, M. (2024) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-024-00574-x · Cited by 1
“The SMAD4 encodes proteins belonging to the SMAD family that are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor β (TGF-β) signaling through multiple pathways [35].”
Characterization of the mode of entry of SG33 oncolytic virus in pancreatic cancer cells
Kontopoulos, N. (2024) · theses.fr (ABES) · doi:10.70675/3c759681z2a9bz424azadf8z7d3fe60d63aa · Cited by 1
Un myélome à immunoglobuline D au cœur du Rendu-Osler
Lejeune, S., Timsit, B. L., Valière, M., Gallet, S., Alban, D., & Bouillet, L. (2018) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.10.121
CHSY3 As A Potential Therapeutic Target For Gastric CancerPreprint
Fan, J., Huang, H., Liang, C., Wang, J., & Liang, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1263603/v1
ВИКОРИСТАННЯ МЕТОДІВ БІОІНФОРМАТИКИ ДЛЯ АНАЛІЗУ КЛІТИННИХ СИГНАЛЬНИХ ШЛЯХІВ
Ковалевська, Л. М., Матвєєва, А. С., & Кашуба, О. В. (2020) · Oncology · doi:10.32471/oncology.2663-7928.t-22-3-2020-g.9204
SMAD4 Gene Analysis in Patients with Early Onset Colorectal Cancer: A Pilot Study
Nikolić, A., Despotović, J., Babič, T., Antic, J. A., Marković, S. Z., Krivokapić, Z., & Radojkovic, D. P. (2022) · Cytology and Genetics · doi:10.3103/s0095452722030082
“SMAD family member 4 (SMAD4, DPC4) is the central mediator of the transforming growth factor beta (TGFB) family of signal transduction proteins involved in many biological processes, including cell growth, differentiation, apoptosis and migration (McCarthy and Chetty, 2018).”
BackgroundLi, J., Xiong, Y., Pi, X., Huang, H., Guo, F., & Pan, H. (2022) · Yangtze Medicine · doi:10.4236/ym.2022.63006
RASAL2 acts as a tumor suppressor in cervical cancer cells
Chen, L., Li, F., CAO, S., LI, X., Chao Hui, Z. H. O. U., Han, S., & Zhang, Y. (2023) · Biocell · doi:10.32604/biocell.2023.027308
Yang, X., Zhang, Q., Li, S., Devarajan, R., Luo, B., Tan, Z., Wang, Z., Giannareas, N., Wenta, T., Ma, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23902905
Paralkar, D., Akbari, A. M., Kandukuri, S. R., & Aron, M. (2024) · International Journal of Surgical Pathology · doi:10.1177/10668969241295350
Koyuncuer, A., Canbak, T., & Acar, A. (2025) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001295
Röcken, C., Amallraja, A., Halske, C., Opašić, L., Traulsen, A., Behrens, H.-M., Krüger, S., Liu, A., Haag, J., Egberts, J.-H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16960609
Röcken, C., Amallraja, A., Halske, C., Opašić, L., Traulsen, A., Behrens, H.-M., Krüger, S., Liu, A., Haag, J., Egberts, J.-H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16960603
Yang, X., Zhang, Q., Li, S., Devarajan, R., Luo, B., Tan, Z., Wang, Z., Giannareas, N., Wenta, T., Ma, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23902902
Germline TGFBR1*6A and colorectal cancer risk
Johansen, A. M. (2025) · WakeSpace Scholarship (Wake Forest University)
Patel, R. (2022) · The Atrium (University of Guelph) · doi:10.1071/rdv34n2ab48
STEVENS, L. (2023) · Queen Mary Research Online (Queen Mary University of London)
Biagini, G., & Zizzo, M. (2021) · IRIS UNIMORE (University of Modena and Reggio Emilia)
張, 夢. (2021) · Institutional Repositories DataBase (IRDB)
Saccone, M. A. (2019) · theses.fr (ABES) · doi:10.70675/d8995276z6866z4372zbbc2z271914e8a438
Metadata
- Authors
- McCarthy, A. J., & Chetty, R.
- Affiliations
- University Health Network (CA)
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2018-05-02
- Volume
- 71
- Issue
- 8
- Pages
- 661-664
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W4229972630
- Cited by
- 71
- References
- 56
- Citations by year
- 2026: 1 · 2025: 12 · 2024: 11 · 2023: 12 · 2022: 12 · 2021: 16 · 2020: 2 · 2019: 3 · 2018: 2
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Pathology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- SMAD4, tumor suppressor, TGF-beta signaling, pancreatic cancer, pancreatic intraepithelial neoplasia, carcinoma in situ, juvenile polyposis syndrome, hereditary hemorrhagic telangiectasia, colorectal cancer, prostate cancer, immunohistochemistry, core needle biopsy, protein localization
- MeSH terms
- Animals, Humans, Mutation, Neoplasms, Biomarkers, Tumor, Signal Transduction, Gene Expression Regulation, Neoplastic, Smad4 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.